Symbol="BLTE"
AssetType="Common Stock"
Name="Belite Bio Inc ADR"
Description="Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, is engaged in the research and development of novel therapies targeting age-related atrophic macular degeneration and autosomal recessive stargardt diseases. The company is headquartered in San Diego, California."
CIK="1889109"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="12750 HIGH BLUFF DRIVE SUITE 475, SAN DIEGO, CA, CA"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="852183000"
EBITDA="-22933000"
PERatio="None"
PEGRatio="None"
BookValue="2.046"
DividendPerShare="0"
DividendYield="0"
EPS="-0.76"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.257"
ReturnOnEquityTTM="-0.435"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-0.76"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="45"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="15.48"
EVToRevenue="-"
EVToEBITDA="-91.18"
Beta="None"
num_52WeekHigh="39.85"
num_52WeekLow="11"
num_50DayMovingAverage="17.53"
num_200DayMovingAverage="25.91"
SharesOutstanding="27226300"
DividendDate="None"
ExDividendDate="None"
symbol="BLTE"
open="26.39"
high="31.80"
low="24.07"
price="31.30"
volume="357246.00"
latest_trading_day="2023-08-18"
previous_close="26.31"
change="4.99"
change_percent="18.9662%"
aroon_positive_momentum_days="2"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="2"
Volume_recent_avg="46289"
Change_recent_avg="0.07"
Delta_recent_avg="1.53"
Variance_recent_avg="0.77"
Change_ratio_recent_avg="0.16"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="2"
Aroon_momentum_negative="98"
image_negative_thumbnail_id_1="1144"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0177.jpeg"
image_negative_thumbnail_id_2="496"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0109.jpeg"
image_neutral_thumbnail_id_1="528"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0071.jpeg"
image_neutral_thumbnail_id_2="560"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0039.jpeg"
image_positive_thumbnail_id_1="1166"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Negative_0187.jpeg"
image_positive_thumbnail_id_2="1016"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0178.jpeg"
image_professor_thumbnail_id_1="1180"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0014.jpeg"
image_professor_thumbnail_id_2="1197"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0031.jpeg"
